Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 23, 2010Expert Opinion on Investigational Drugs

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

SASébastien AlbertAgroParisTechMSMaria SerovaSechenov UniversityCDChantal DreyerGroupe Hospitalier Diaconesses Croix Saint-Simon

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Albert et al. (2010) studied this question.

synapsesocial.com/papers/6a75162f0081fe7b05dc02bfhttps://doi.org/10.1517/13543784.2010.499121
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.1632009 · 262 citations
  2. 2Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts2009 · 124 citations
  3. 3Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo2005 · 244 citations
  4. 4mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?2008 · 120 citations
  5. 5mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt2006 · 2,599 citations